Navigation Links
Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim's Two Investigational HCV Direct Acting Antivirals Presented at AASLD
Date:11/7/2011

ronic HCV will develop cirrhosis within 20 years of infection. The mortality rate after cirrhosis has developed is 2 – 5 percent per year.

About Boehringer Ingelheim in Hepatitis C Virus

Boehringer Ingelheim has a long-standing commitment to virology, including developing innovative therapies for HIV/AIDS and HCV. The company recognizes the significance of the HCV epidemic and continues to work on improving treatment and cure rates for diverse populations of HCV patients through its dedicated HCV treatment development program, called HCVerso™.

Boehringer Ingelheim is advancing BI 201335, an investigational oral HCV NS3/4A protease inhibitor that has the potential to improve cure rates as compared to PegIFN/RBV therapy. A multi-study Phase 3 trial program currently is underway to evaluate BI 201335 combined with PegIFN/RBV in both treatment-naive and -experienced patients with chronic genotype-1 HCV.

Boehringer Ingelheim also is developing BI 207127, an NS5B RNA-dependent polymerase inhibitor that has the potential to eliminate interferon from HCV treatment when combined with BI 201335 and RBV. Phase 2 trials evaluating BI 207127 with BI 201335 in interferon-sparing regimens, with and without RBV, are currently underway.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

A
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
2. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
3. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
4. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
5. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
6. Hepatitis C Phase 2A Trial Positive Results
7. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
8. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
9. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
10. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
11. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Agena Bioscience TM today announced the ... a commercial and financial hub from which many biotech and ... laboratories in mainland China . ... global sales with almost sixty MassARRAY ® Systems installed ... will allow us to expand our reach and foster a ...
(Date:9/1/2015)... In nur zwei Jahren nach dem ... SHL Group schnell weltweit 3.000 Mitarbeiter erreicht. Diese ... dem Markt der injizierbaren Medikamente und ... von SHL wieder. Foto - ... in Design und Herstellung automatischer Injektoren und Pen-Injektoren ...
(Date:9/1/2015)... WAYNE, Pa. , Sept. 1, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced that researchers will be  presenting scientific data ... Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, ... in development, at PainWeek 2015 to ...
Breaking Medicine Technology:Agena Bioscience Opens Office in Shanghai, China 2SHL Group erreicht wichtigen Markstein von 3.000 Mitarbeitern 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 2Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 3Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 4Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 5Egalet Announces Scientific Presentations at PainWeek 2015 Meeting 6
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... From Aug. ... children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough ... included 65 adult counselors, some of whom work for Calvary, and two junior counselors ...
(Date:9/1/2015)... ... September 01, 2015 , ... Horizon Blue Cross Blue Shield of New ... Latinas in the LATINA Style 50 Report that recognizes companies that provide the best ... 2015, Horizon BCBSNJ climbs from number 24 to 21 of the 50 Best Companies ...
(Date:9/1/2015)... UK (PRWEB) , ... September ... ... constantly seeking better therapeutic options to efficiently cure and prevent different malignancies. ... Different cancers have different pathophysiological properties due to which distinctive approach is ...
(Date:9/1/2015)... ... 2015 , ... As part of its ongoing commitment to ... (Blue Cross) has announced Doctor On Demand as the company’s preferred telehealth service ... provides immediate access to Board Certified physicians or next-day appointments with psychologists from ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure wound therapy (NPWT) ... to remove exudates, fluid, and infectious materials to prepare the wound for healing ... devices, and canisters, etc.) is projected to expand continuously through 2021. , Rising ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
... WAYNE, Pa., Sept. 28 Escalon Medical Corp.,(Nasdaq: ... quarter and,twelve months ended June 30, 2007. For ... increased,to $38,837,780 compared with $29,790,698 in fiscal 2006. This ... million lump sum settlement payment,from IntraLase Corp. to the ...
... Sanarus Medical today announced a,partnership with leading ... These Centers, including breast care physicians from,Connecticut to ... the awareness and availability of an innovative, non-surgical,treatment ... as,fibroadenomas. Sanarus will host a gathering of these ...
... she is giving a,keynote address or visiting on the ... and possibility. "Only in America could someone like ... warm laugh, "I,m a physically disabled woman whose,father is ... temples,and I,m running for Town Council as a Republican." ...
... pressure to combat,childhood obesity, the market for licensed foods ... breaking the $1,billion mark in 2011, according to Kids, ... from market research publisher Packaged Facts. Between 2002 ... and,beverage products rose 9%, from $684 million to $746 ...
... A 6-month diet restored normal blood pressure, study finds , , ... identified overweight as a direct cause of high blood pressure. ... people can bring down blood pressure to healthy levels by ... achieved before the borderline to outright obesity is crossed, said ...
... Blue Cross Blue Shield of Michigan is,partnering with ... in,five Michigan cities to help enroll eligible uninsured children ... to urge community leaders and small,business owners to help ... Attendees will be asked to send their staffs to ...
Cached Medicine News:Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 3Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 4Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 5Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 6Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 7Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2Health News:Humor and Hope Sustain NJ Woman Through Disabling Movement Disorder, Election Campaign 2Health News:Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids' Licensed Foods and Beverages 2Health News:Weight Loss Can Control Hypertension 2Health News:Weight Loss Can Control Hypertension 3Health News:Blue Cross Blue Shield of Michigan Launches Effort in Five Michigan Cities with Department of Community Health to Enroll Uninsured Children in MIChild 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: